Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibitors of protease activated receptor-2

A -NH2, -C1-C20 technology, applied in the field of PAR2 inhibitors, the treatment of diseases and disorders mediated by PAR2 signaling

Pending Publication Date: 2020-09-22
TAKEDA PHARMA CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, it has been demonstrated that administration of PAR in vivo 2 Agonists cause an inflammatory response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitors of protease activated receptor-2
  • Inhibitors of protease activated receptor-2
  • Inhibitors of protease activated receptor-2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0298] Example 1: Synthesis of ethyl 6-chloroimidazo[1,2-b]pyridazine-2-carboxylate (step (a) of general synthesis scheme 1)

[0299]

[0300] In a 1 L round bottom flask was added 6-chloropyridazin-3-amine (30 g, 0.2316 mol) dissolved in DMF (300 mL). Then ethyl 3-bromo-2-oxo-propionate (38 mL, 0.3 mol) was added in portions. The mixture was kept at 50°C for 1.5 hours. The mixture was cooled to room temperature with a water / ice bath, and water (600 mL) was added dropwise to the reaction mixture over 2 hours. It was then stirred overnight at room temperature. The formed precipitate was filtered off by filtration (approximately 30 minutes) on a Buchner funnel. The precipitate was washed with 3x500 mL of water and dried under vacuum on a Buchner funnel for 2 hours and then in a vacuum oven at 40 °C for 20 hours to give 6-chloroimidazo[2,l-b]pyridazine-2-carboxylic acid The ethyl ester (29.9 g, 57%) was a yellow solid. 1 H NMR (401MHz, DMSO) δ8.85(s, 2H), 8.27(d, J=9.6Hz,...

Embodiment 2

[0301] Example 2: Synthesis of ethyl 8-tert-butyl-6-chloroimidazo[1,2-b]pyridazine-2-carboxylate (step (b) of General Synthesis Scheme 1)

[0302]

[0303] Equipped with a dropping funnel, N 2 A 1 L 3-neck round bottom flask with inlet and condenser was charged with water (98.10 mL) and trifluoroacetic acid (10.72 mL, 139.1 mmol). Once the exotherm was over, ethyl 6-chloroimidazo[2,l-b]pyridazine-2-carboxylate (21 g, 92.72 mmol), 2,2-dimethylpropionic acid (37.88 g, 21.30 mL, 370.9 mmol) and acetonitrile (200mL), then add AgNO 3 (7.88 g, 46.36 mmol). The reaction mixture was wrapped in aluminum foil and heated to 80 °C. A solution of ammonium persulfate (35.24 g, 166.9 mmol) in water (98.10 mL) was added via the dropping funnel over 30 minutes. After the addition was complete, the addition funnel was removed and the mixture was fitted with a condenser and heated at 80°C for 30 minutes.

[0304] The reaction was then cooled to room temperature and diluted with 200 mL of...

Embodiment 3

[0306] Example 3: Synthesis of ethyl 8-tert-butyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carboxylate (step (c) of General Synthesis Scheme 1)

[0307]

[0308] To a solution of ethyl 8-tert-butyl-6-chloroimidazo[l,2-b]pyridazine-2-carboxylate (500 mg, 1.755 mmol) in DMF (7 mL) was added (4-fluorophenyl)boronic acid (280mg, 2.004mmol), PdCl 2 (dppf) 2 -DCM (30mg, 0.03644mmol) and Na 2 CO 3 (1.822 mL, 2M, 3.644 mmol). use N 2 After degassing by bubbling for 5 minutes, it was heated at 80° C. for 18 hours. Water was added along with ethyl acetate and the phases were separated. The organic phase was washed twice with water and brine (1:1 mixture), washed over MgSO 4 Drying, filtration and evaporation under reduced pressure afforded ethyl 8-tert-butyl-6-(4-fluorophenyl)imidazo[l,2-b]pyridazine-2-carboxylate (545 mg, 90%) as solid. 1 H NMR (401MHz, DMSO) δ8.79(s, 1H), 8.20-8.11(m, 2H), 7.51(s, 1H), 7.46-7.38(m, 2H), 4.36(q, J=7.1Hz, 2H), 1.60 (s, 9H), 1.34 (t, J =...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates generally to compounds capable of inhibiting Protease Activated Receptor-2 (PAR2), and uses thereof. More specifically, the present invention relates to inhibitors of PAR2, to their preparation, and to their use in the treatment of diseases and disorders mediated by PAR2 signaling.

Description

technical field [0001] The present invention generally relates to proteins capable of inhibiting protease-activated receptor-2 (PAR 2 ) compounds and uses thereof. More specifically, the present invention relates to PAR 2 Inhibitors, related to their preparation and their use in the treatment by PAR 2 Use in signaling mediated diseases and conditions. Background technique [0002] Protease-activated receptors (PARs) comprising PAR-1, -2, -3, and -4 are a family of G protein-coupled receptors (GPCRs) with a unique mechanism of activation. PAR is not directly activated by endogenous ligands, but indirectly by the proteolytic action of enzymes such as thrombin, tissue factor, cathepsin S, tryptase, or trypsin. Typically, proteolytic enzymes cleave a portion from the N-terminus of the PAR, exposing a new N-terminus, which folds up and activates the receptor as an endogenous tethered ligand. The specific cleavage sites for PARs differ in amino acid sequence and are thus reco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5025C07D487/04A61P25/00A61P29/00A61P35/00
CPCA61K31/5025C07D487/04A61P25/00A61P29/00A61P35/00A61K47/65C07D235/02
Inventor L·奥雷里奥N·邦内特B·L·弗林L·江
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com